*Applications will be reviewed on a rolling-basis.
A research opportunity is currently available with the Office of Blood Research and Reviews (OBRR), at the Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA) located in Silver Spring, Maryland.
This project has 2 specific aims focusing on hepatitis viruses that threaten the blood supply providing training to the participant in diagnostic assay development and the study of pathogenesis of blood-borne hepatitis viruses. In addition, the participant will have the opportunity to participate in other regulatory science applications associated with emerging infectious diseases.
Aim 1: Development of cell culture systems, novel detection assays and reference reagents for hepatitis E virus genotypes with zoonotic potential.
In industrialized countries sporadic HEV infections are caused by genotypes 3, 4 and 7 HEV. These viruses primarily infect animals such as pigs and deer but can be transmitted to humans by consumption of undercooked meat from infected animals. Most infections with these food-borne HEV strains have no symptoms so infected individuals may feel well enough to donate blood. When blood products containing HEV are given to immune suppressed persons (e.g. organ transplant recipients), the virus can establish chronic infection and cause progressive liver disease. For this reason, HEV is considered an emerging threat to blood safety. Goals under this specific aim include (i) improvement of cell culture systems for HEV genotype 3, 4 and 7 as well as rat HEV (Orthohepevirus C) (ii) development of novel and sensitive methods for detection of HEV in blood using assays that target a secreted form of the viral capsid (iii) development of reference reagents for the standardization of diagnostic tests between different laboratories. Under the guidance of a mentor, the participant will receive training in molecular virology and cell biology methods including virus propagation in cell culture, virus detection and quantitation, infectivity assays, virus purification and biochemical characterization, genetic sequencing, protein expression, ELISA, RT-qPCR, etc.
Aim 2: Studies of pathogenesis of blood-borne hepatitis viruses
Disease progression and outcomes are variable following exposure to and infection with blood-borne hepatitis viruses. This study will identify mechanisms of pathogenesis during acute and chronic infection with HBV and HCV. The study is a collaboration with NIH and makes use of well-characterized clinical specimens from patients with acute and chronic viral hepatitis with a wide range of disease outcomes. Under the guidance of a mentor, the participant will use multidisciplinary approaches (including in vitro and animal studies as well as characterization of clinical specimens) to investigate the molecular mechanisms that contribute to disease progression. The participant will receive training in the use of ex vivo (primary hepatocyte) models of HBV and HCV infection, RT-qPCR, in situ hybridization, confocal microscopy, etc.
In addition to the training activities described in the two aims above, our lab supports the development of reference panels for the evaluation of diagnostic tests for emerging infectious diseases such as SARS-CoV-2 (the agent that causes Covid-19). The participant will have the opportunity to contribute to the development of reference panels for SARS-CoV-2.
Anticipated Appointment Start Date: September 1, 2020
This program, administered by ORAU through its contract with the U.S. Department of Energy to manage the Oak Ridge Institute for Science and Education, was established through an interagency agreement between DOE and FDA. The initial appointment is for one year, but may be renewed upon recommendation of FDA contingent on the availability of funds. The participant will receive a monthly stipend commensurate with educational level and experience. Proof of health insurance is required for participation in this program. The appointment is full-time at FDA in the Silver Spring, Maryland, area. Participants do not become employees of FDA, DOE or the program administrator, and there are no employment-related benefits.
The qualified candidate should have received a master’s or doctoral degree in one of the relevant fields, or be currently pursuing one of the degrees and will reach completion by the appointment start date. Degree must have been received within five years of the appointment start date.
If you have questions, send an email to ORISE.FDA.CBER@orau.org. Please include the reference code for this opportunity (FDA-CBER-2020-0032) in your email.